German fragrances and flavours developer and supplier BASF Aroma Ingredients has introduced Isobionics Natural alpha-Farnesene 95, a new ingredient aimed at lime-related applications.
The launch expands the company’s Isobionics line of natural flavour compounds produced using fermentation technology.
According to the company, the ingredient has a purity level exceeding 95% and is suitable for use in lime essential oils, beverages, sweets and other citrus and fruit-based formulations.
BASF described Isobionics Natural alpha-Farnesene 95 has a “vegetable odour, with celery note followed by sappy, plant stem-like note, and fruit skin,” and at 10 ppm, it offers a “sappy, slightly floral, waxy apple/pear skin, citrus, some white flower and ocimene notes”.
BASF Aroma Ingredients senior vice president Steffen Götz said: “We are excited to introduce our new flavour ingredient, Isobionics Natural alpha-Farnesene 95, to the market. This product represents our strong commitment to providing our customers with innovative high-quality aroma ingredients.
“Like all Isobionics products, Isobionics Natural alpha-Farnesene 95 is fermentation-based and produced from renewable resources.”
The product complies with European Union and the US food-grade regulations, registered under FLAVIS number 01.040 and FEMA number 3839.
The launch adds to BASF Aroma Ingredients’ line-up for lime applications, which also includes Isobionics Natural beta-Bisabolene 90, Isobionics Natural trans-alpha-Bergamotene 80 and Isobionics Natural beta-Caryophyllene 80.
BASF flavour launch manager Giovanni D’Andola added: “Isobionics Natural alpha-Farnesene 95 completes our lime oil natural sesquiterpene ingredient portfolio.
“We’re proud to offer this extensive range of flavour ingredients for our customers’ lime applications, which is unique in the market.”
In December 2024, plant-based ingredients provider Louis Dreyfus Company (LDC) signed a binding agreement to acquire BASF’s Food and Health Performance Ingredients business.
The deal included a production site, an advanced research and development (R&D) centre in Illertissen, Germany, and three application labs outside Germany.
Financial details of the deal were not disclosed by the parties.
